Gefjon Pharma ApS
Nøgletal
- Afkastningsgrad
- -55,9 %
- Egenkapitalforrentning
- –
- Likviditetsgrad
- 415,1 %
- Soliditetsgrad
- -63,5 %
Resultat
| Regnskabsperiode | |
|---|---|
Bruttoresultat | -2.230.382 |
Driftsresultat | -4.402.019 |
Finansielle indtægter | 22 |
Finansielle omkostninger | 663.147 |
Skat af årets resultat | -819.691 |
Årets resultat | -4.245.453 |
Medarbejdere
| Regnskabsperiode | |
|---|---|
Gns. ansatte | 5 |
Personaleomkostninger | 2.171.637 kr. |
Balance
| Regnskabsperiode | |
|---|---|
Likvider | 6.963.041 |
Kortfristede aktiver | 7.867.883 |
Aktiver i alt | 7.867.883 |
Egenkapital | -4.998.334 |
Forpligtelser i alt | 12.866.217 |
Kortfristede forpligtelser | 1.895.191 |
Arbejdskapital
| Regnskabsperiode | |
|---|---|
Andre kortfristede tilgodehavender | 79.532 |
Leverandørgæld | 130.603 |
Kapital og udbytte
| Regnskabsperiode | |
|---|---|
Selskabskapital | 40.000 |
Overført resultat | -5.038.334 |
Højdepunkter fra årsrapporten
Forretning og udvikling
The Company continues to develop and commercialize next-generation pharmaceutical and bio-industrial solutions based on its proprietary outer membrane vesicle (OMV) platform with the lead asset being our E. coli vaccine targeting poultry. The primary focus remains the development of the lad asset, designed for mass administration via aerosol.
The income statement of the Company for 2025/26 shows a loss of DKK 4,245,453, and at 31 March 2026 the balance sheet of the Company shows a negative equity of DKK 4,998,334
Development in activities and financial mattersDuring the financial year, Gefjon Pharma has significantly advanced both its lead asset and organizational capabilities, transitioning from early validation into a more execution-driven and investor-ready stage.…
Risici og væsentlige forhold
The Company has for the financial year presented a negative result of DKK 4,245 thousand, has a cash position of DKK 6,963 thousand and negative equity of DKK 4,998 thousand as of 31 March 2026.Based on the cash position at year-end and the latest approved budget, the Company has a run rate until at a minimum June 2027. The budget does not take into account discretionary cuts to spending, or potential investor investments in the Company. Accordingly, it is Management's assessment that there is no material uncertainty related to going concern.
Forpligtelser og sikkerhedsstillelser
The Company has entered into rental agreements with a 3-month notice period, with commitment 31 march 2026 amounting to DKK 62 thousand.Other than this, the Company has not entered into any mutually binding agreements as of the balance sheet date that affect the Company's financial position.
Se op til 9 års regnskabshistorik ved at oprette en gratis bruger
Opret gratis bruger